GSTA4

Across TCGA pan-cancer cohorts, GSTA4 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated GSTA4 data layer compared with 25 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher GSTA4 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated GSTA4 expression acts as an unfavorable survival marker, although some lineages such as PDAC and CCRCC show a favorable association.

PDAC, CCRCC, and LSCC are the cancer types where GSTA4 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	II,III,IV	0.471	0.309	.008	28	view →
CCRCC	OS	Tertile	All	1.000	0.865	.008	20	view →
LSCC	DFS	Median	II,III,IV	0.858	0.520	.004	17	view →
LUAD	DFS	Median	II,III,IV	0.780	0.921	.039	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

GSTA4–PDAC (DFS)

Open the PDAC breakdown →